<DOC>
	<DOCNO>NCT01964027</DOCNO>
	<brief_summary>This study determine response rate safety profile irinotecan plus epirubicin second-line chemotherapy advance gastric cancer fully evaluate feasibility effectiveness regime .</brief_summary>
	<brief_title>The Study Irinotecan Plus Epirubicin Second-line Chemoregime Advanced Gastric Cancer</brief_title>
	<detailed_description>The main purpose : determine progression-free survival ( PFS ) overall survival ( OS ) gastric cancer patient give irinotecan + epirubicin second-line treatment , Stage IV disease progress recurred first-line chemotherapy fail , , The Secondary purpose : determine disease control rate ( Disease Control Rate , DCR ) , objective response rate ( Object Response rate , ORR ) Quality life ( Quality Of Life , QOL )</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>Inclusion criterion : Aged 18 70 year The pathologically confirm gastric adenocarcinoma failure firstline chemotherapy Measurable lesion outside stomach ECOG ( Eastern Cooperative Oncology Group ) score 0 1 Expected survival time least 3 month Subjects receive treatment damage cause restore , accept nitroso mitomycin interval &gt; 6 week , acceptance cytotoxic drug , radiotherapy surgery &gt; = 4 week , wind completely heal . No bleeding , nervous system transfer Blood organ function normal Exclusion criterion : Comorbid malignant tumor Pregnant lactate woman disease endanger patient 's safety affect completion study Patients suffer high blood pressure antihypertensive treatment control ( systolic blood pressure &gt; 140mmhg , diastolic blood pressure &gt; 90mmhg , ) Class I Class I arrhythmia coronary heart disease , Class I heart dysfunction Major organ failure , decompensated heart lung failure , liver failure , renal failure patient intestinal obstruction ipate clinical trial patient past four week Participated clinical trial drug use drug past 4 week Lesions ca n't measure pleural effusion , ascites , peritoneal cancer lesion , diffuse liver bone metastases violation , brain metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>second line chemoregime</keyword>
	<keyword>gastric cancer</keyword>
</DOC>